2020
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.
Piccart MJ, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, Naït Kaoudjt R, Schumacher E, Spears PA, Regan MM, Gelber RD, Davidson NE, Norton L, Winer EP. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. Journal Of Clinical Oncology 2020, 38: 4120-4129. PMID: 33052755, DOI: 10.1200/jco.20.01382.Peer-Reviewed Original ResearchConceptsDe-escalation trialsNorth American Breast Cancer GroupBreast International GroupTreatment de-escalation trialsSystemic adjuvant therapySystemic adjuvant treatmentBreast cancer groupNoninferiority trial designAdjuvant trialsAdjuvant therapyAdjuvant treatmentCancer groupDifferent cancer typesPatient insightPatient's perspectiveEffective treatmentConsensus articleTrial designSolid tumorsField of cancerEnd pointFinancial toxicityCancer typesTrialsAdverse effects
2007
Association between pharmaceutical involvement and outcomes in breast cancer clinical trials
Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 2007, 109: 1239-1246. PMID: 17326054, DOI: 10.1002/cncr.22528.Peer-Reviewed Original ResearchConceptsBreast cancer clinical trialsCancer clinical trialsPharmaceutical involvementClinical researchClinical trialsPharmaceutical industry involvementBreast cancer clinical researchSingle-arm studyDisease-specific outcomesClinical breast cancer researchCancer clinical researchBreast cancer researchEnglish-language medical journalsPharmaceutical industry fundingProvision of drugsMetastatic diseaseMedical therapyEligible studiesBreast cancerClinical studiesTrial designStudy designUnpublished studiesHealth fundingPharmaceutical industry support